Acquisitions usually depress the stock price of the buyer to reflect the dilution and propel the shares of the acquired to reflect the premium. But not always.

The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.

Following a deal, worth potentially $700m plus, signed in 2015 with Johnson & Johnson’s Janssen Biotech, Swedish biotech Alligator Biosciences AB is well placed to drive its clinical pipeline. During the Biotech Showcase, CEO Per Norlén outlined to Scrip the current status of the pipeline and its plans moving forward, which include having five clinical programs in place by the end of 2019.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.